As of 2026-10-12, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.32. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,477.38 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 47.4x - 67.3x | 59.3x |
| Forward P/E multiples | 22.1x - 31.5x | 27.6x |
| Fair Price | (32.60) - (21.23) | (29.76) |
| Upside | -239.7% - -191.0% | -227.6% |
| Date | EV/EBITDA |